Cart
sales@molnova.com
SU5208
CAS No. 62540-08-3
SU5208( 3-[(Thien-2-yl)methylene]-2-indolinone )
Catalog No. M22956 CAS No. 62540-08-3
SU5208 is a compound with bioactivity.SU5208 inhibits vascular endothelial growth factor receptor-2 (VEGFR2).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 268 | In Stock |
|
| 10MG | 405 | In Stock |
|
| 25MG | 668 | In Stock |
|
| 50MG | 888 | In Stock |
|
| 100MG | 1251 | In Stock |
|
| 500MG | 2538 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSU5208
-
NoteResearch use only, not for human use.
-
Brief DescriptionSU5208 is a compound with bioactivity.SU5208 inhibits vascular endothelial growth factor receptor-2 (VEGFR2).
-
DescriptionSU5208 is a compound with bioactivity.SU5208 inhibits vascular endothelial growth factor receptor-2 (VEGFR2).
-
In Vitro——
-
In Vivo——
-
Synonyms3-[(Thien-2-yl)methylene]-2-indolinone
-
PathwayAngiogenesis
-
TargetVEGFR
-
RecptorVEGFR2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number62540-08-3
-
Formula Weight227.28
-
Molecular FormulaC13H9NOS
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (439.99 mM)
-
SMILESO=C1NC2=C(C=CC=C2)/C1=C/C3=CC=CS3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Camila Mu?oz, et al. Study of differences in the VEGFR2 inhibitory activities between semaxanib and SU5205 using 3D-QSAR, docking, and molecular dynamics simulations. J Mol Graph Model. 2012 Feb;32:39-48.
molnova catalog
related products
-
Pazopanib
A potent, orally available, pan-VEGFR inhibitor with IC50 of 10, 30, and 47 nM for VEGFR-1, -2, and -3, respectively.
-
Takeda-6d
Takeda-6d is a novel, potent DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with IC50 of 7.0 nM and 2.2 nM, respectively.
-
Regorafenib hydrochl...
Regorafenib hydrochloride (BAY73-4506) is a potent, orally active multikinase inhibitor.
